U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07152405) titled 'A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma' on Aug. 26.
Brief Summary: This trial is a registrational Phase III, randomized, controlled, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction (G/GEJ) adenocarcinoma after failure of first-line anti-HER2 therapy and first-line standard chemotherapy.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition: ...